Neurocrine Biosciences Inc
(NAS:NBIX)
$
136.53
-0.46 (-0.34%)
Market Cap: 13.82 Bil
Enterprise Value: 12.85 Bil
PE Ratio: 36.60
PB Ratio: 5.08
GF Score: 88/100 Neurocrine Biosciences Inc at Robert W Baird Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021 / 02:50PM GMT
Release Date Price:
$96.34
(+1.82%)
Brian Peter Skorney
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
All right. Good morning, everyone. Welcome back to Baird's Healthcare Conference. I'm Brian Skorney, I'm one of Baird's senior biotech analysts. Really happy to have with me as the next fireside chat presentation the management of Neurocrine Biosciences. We have Matt Abernethy, the CFO of Neurocrine and Eiry Roberts, the Chief Medical Officer of Neurocrine. Matt, Eiry, thanks so much for joining us today.
Questions & Answers
Brian Peter Skorney
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
Maybe to just kind of start off, you can give us an overview of your business model, what areas you're focused on from a commercial and development perspective, and how success of INGREZZA, your lead commercial product pipeline expansion, evolve your focus?
Matthew C. Abernethy
Neurocrine Biosciences, Inc. - CFO
Sure, Brian. Thanks for hosting us. And I would say we're going to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot